Contributes to Mammary Carcinogenesis Production of Tumor Necrosis Factor That Critically Oncogene-Driven Intrinsic Inflammation Induces Leukocyte

Oncogene activation promotes an intrinsic inflammatory pathway that is crucial for cancer development. Here, we have investigated the actual effect of the inflammatory cytokine tumor necrosis factor (TNF) on the natural history of spontaneous mammary cancer in the HER2/neuT (NeuT) transgenic mouse model. Bone marrow transplantation from TNF knockout mice into NeuT recipients significantly impaired tumor growth, indicating that the source of TNF fostering tumor development was of bone marrow origin. We show that the absence of leukocyte-derived TNF disarranged the tumor vasculature, which lacked pericyte coverage and structural integrity, leading to diffuse vascular hemorrhage and stromal necrosis. In addition, tumor-associated Tie2 – expressing monocytes were reduced and cytokine expression skewed from Th2 to Th1 type. Treatment of NeuT mice with anti-TNF antibody partially phenocopied the antitumor effect of TNF-deficient bone marrow cell transplantation, providing a strong preclinical background and rationale for the introduction of TNF antagonists in the treatment of human breast cancer, including basal-like samples for which consolidated targeted therapies do not exist. Cancer Res; 70(20); 7764 – 75. ©2010 AACR.

[1]  George Kollias,et al.  The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. , 2009, The Journal of clinical investigation.

[2]  W. Bshara,et al.  Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice , 2009, Molecular Cancer Therapeutics.

[3]  A. Sica,et al.  A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. , 2009, Blood.

[4]  F. Balkwill.  Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[5]  G. Ahn,et al.  Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: Experimental models and clinical perspectives , 2009, Cell cycle.

[6]  E. Iannitto,et al.  CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis , 2009, Haematologica.

[7]  J. Edwards,et al.  Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.

[8]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[9]  Christopher C W Hughes,et al.  TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. , 2008, Blood.

[10]  N. Mukaida,et al.  Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. , 2008, The Journal of clinical investigation.

[11]  M. Gore,et al.  Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Hagemann,et al.  The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. , 2007, Cancer research.

[13]  F. Balkwill.  TNF-α in promotion and progression of cancer , 2006, Cancer and Metastasis Reviews.

[14]  P. Szlosarek,et al.  Tumour necrosis factor-α as a tumour promoter , 2006 .

[15]  Luigi Naldini,et al.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.

[16]  T. Ganesan,et al.  Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Z. Werb,et al.  PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival , 2005, Nature Cell Biology.

[18]  G. Trinchieri,et al.  Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. , 2005, Cancer research.

[19]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[20]  M. R. Powers,et al.  Altered Retinal Neovascularization in TNF Receptor–Deficient Mice , 2005, Current eye research.

[21]  A. Harris,et al.  A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[22]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[23]  M. Karin,et al.  Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression , 2004 .

[24]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[25]  F. Balkwill,et al.  Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development , 2004, Oncogene.

[26]  W. Min,et al.  Etk/Bmx Transactivates Vascular Endothelial Growth Factor 2 and Recruits Phosphatidylinositol 3-Kinase to Mediate the Tumor Necrosis Factor-induced Angiogenic Pathway* , 2003, Journal of Biological Chemistry.

[27]  M. Colombo,et al.  Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma , 2003, The Journal of experimental medicine.

[28]  P. Szlosarek,et al.  Tumour necrosis factor α: a potential target for the therapy of solid tumours , 2003 .

[29]  Robert J. Moore,et al.  An Anti-Tumor Necrosis Factor-α Antibody Inhibits the Development of Experimental Skin Tumors , 2003 .

[30]  N. Mukaida,et al.  Accelerated wound healing in tumor necrosis factor receptor p55‐deficient mice with reduced leukocyte infiltration , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  N. Fausto,et al.  Impaired Preneoplastic Changes and Liver Tumor Formation in Tumor Necrosis Factor Receptor Type 1 Knockout Mice , 2000, The Journal of experimental medicine.

[32]  G. Kollias,et al.  Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis , 1999, Nature Medicine.

[33]  S. Soker,et al.  Tumor Necrosis Factor-α Regulates Expression of Vascular Endothelial Growth Factor Receptor-2 and of Its Co-receptor Neuropilin-1 in Human Vascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[34]  Piero Musiani,et al.  Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.

[35]  E. Haber,et al.  Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. , 1996, The Journal of clinical investigation.

[36]  D. Miles,et al.  Expression of tumour necrosis factor (TNFα) and its receptors in benign and malignant breast tissue , 1994 .

[37]  A. Villa,et al.  Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. , 1992, Cancer letters.

[38]  W. Risau,et al.  Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  N. Sato,et al.  Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. , 1986, Journal of the National Cancer Institute.

[40]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.

[41]  B. Aggarwal,et al.  Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity , 1984, Nature.

[42]  D. Fraker,et al.  TNF-α downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model , 2003 .